Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesGenitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose–Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity
International Journal of Radiation Oncology*Biology*Physics, 08/31/09
Ishiyama H et al. – The severity of GU toxicity in HDR brachytherapy combined with hypofractionated EBRT for prostate cancer was relatively high. The volume of prostatic urethra was associated with grade of acute GU toxicity, and urethral dose was associated with grade of late GU toxicity.
Today in Radiotherapy (XRT)...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence
European Journal of Cancer, 11/05/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/11/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Sponsor
Article Search
Sponsor